MYRIAD GENETICS, INC. Net Change in Cash
MYRIAD GENETICS, INC. (MYGN) reported Net Change in Cash of -$34.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-31
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$25.30M.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$10.90M.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$35.30M.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$3.30M.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $39.40M.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$29.00M, a 138.93% decline from fiscal 2023.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $74.50M.
- MYRIAD GENETICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$192.40M, a 235.68% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$34.50M 10-Q · filed 2026-07-31 | ||||||
| 2026-03-31 | -$25.30M 10-Q · filed 2026-05-06 | ||||||
| 2025-12-31 | $39.40M 10-K · filed 2026-02-24 | ||||||
| 2025-09-30 | $42.90M 10-Q · filed 2025-11-04 | ||||||
| 2025-06-30 | -$28.20M 10-Q · filed 2026-07-31 | ||||||
| 2025-03-31 | -$10.90M 10-Q · filed 2026-05-06 | ||||||
| 2024-12-31 | -$29.00M 10-K · filed 2026-02-24 | ||||||
| 2024-09-30 | -$31.10M 10-Q · filed 2025-11-04 | ||||||
| 2024-06-30 | -$39.70M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | -$35.30M 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | $74.50M 10-K · filed 2026-02-24 | ||||||
| 2023-09-30 | $18.60M 10-Q · filed 2024-11-08 | ||||||
| 2023-06-30 | $46.30M 10-Q · filed 2024-08-07 | ||||||
| 2023-03-31 | -$3.30M 10-Q · filed 2024-05-08 | ||||||
| 2022-12-31 | -$192.40M 10-K · filed 2025-02-28 | ||||||
| 2022-09-30 | -$148.10M 10-Q · filed 2023-11-07 | -$147.70M 10-Q · filed 2022-11-02 | |||||
| 2022-06-30 | -$152.60M 10-Q · filed 2023-08-04 | -$153.20M 10-Q · filed 2022-08-05 | |||||
| 2022-03-31 | -$93.20M 10-Q · filed 2023-05-04 | ||||||
| 2021-12-31 | $141.80M 10-K · filed 2024-02-28 | $141.40M 10-K · filed 2022-02-25 | |||||
| 2021-09-30 | $178.20M 10-Q · filed 2022-11-02 | ||||||
| 2021-06-30 | $1.40M 10-Q · filed 2022-08-05 | ||||||
| 2021-03-31 | $31.90M 10-Q · filed 2022-05-06 | ||||||
| 2020-12-31 | -$46.70M 10-K · filed 2023-03-01 | ||||||
| 2020-09-30 | -$45.40M 10-Q · filed 2020-11-09 | $37.10M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $82.50M 10-Q · filed 2021-08-04 | $70.50M 10-K · filed 2023-03-01 | |||||
| 2020-03-31 | $39.80M 10-Q · filed 2021-05-05 | $27.80M 10-Q · filed 2020-05-06 | |||||
| 2019-12-31 | -$12.00M 10-Q · filed 2020-02-07 | ||||||
| 2019-09-30 | -$3.30M 10-Q · filed 2020-11-09 | ||||||
| 2019-06-30 | -$17.70M 10-K · filed 2022-02-25 | ||||||
| 2019-03-31 | -$26.00M 10-Q · filed 2020-05-06 | ||||||
| 2018-12-31 | -$20.30M 10-Q · filed 2020-02-07 | ||||||
| 2018-09-30 | -$17.60M 10-Q · filed 2019-11-06 | ||||||
| 2018-06-30 | $8.50M 10-KT · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |